• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

外周动脉疾病的保守治疗

[Conservative treatment of peripheral arterial disease].

作者信息

Espinola-Klein Christine, Weißer Gerhard

机构信息

Zentrum für Kardiologie/Kardiologie III - Angiologie, Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Langenbeckstraße 1, 55131, Mainz, Deutschland.

出版信息

Inn Med (Heidelb). 2022 Jun;63(6):579-583. doi: 10.1007/s00108-022-01342-8. Epub 2022 May 9.

DOI:10.1007/s00108-022-01342-8
PMID:35532800
Abstract

Patients with peripheral arterial disease (PAD) often have polyvascular atherosclerosis and are at increased risk of major adverse cardiovascular events (MACE), such as cardiovascular death, myocardial infarction or stroke, and major adverse limb events (MALE), such as amputation and acute limb ischemia. Therefore, the aim of conservative treatment is the reduction of MACE and MALE. In patients with intermittent claudication, the aim is also to extend walking distance. Management of risk factors includes smoking cessation, statin therapy, reduction of low-density lipoprotein cholesterol (target < 55 mg/dL and reduction to at least 50% of baseline value), normalization of blood glucose and treatment of arterial hypertension (target < 140/90 mm Hg). Moreover, antithrombotic treatment should include antiplatelet therapy (acety salicylic acid 100 mg or clopidogrel 75 mg). In patients at high thrombotic risk and low bleeding risk combination of acetlylic acid 100 mg and rivaroxaban 2 × 2.5 mg is indicated. In patients with intermittent claudication exercise therapy is highly recommended. Despite the high risk, in particular patients with PAD are often undertreated in clinical practice.

摘要

外周动脉疾病(PAD)患者常患有多血管动脉粥样硬化,发生主要不良心血管事件(MACE)的风险增加,如心血管死亡、心肌梗死或中风,以及主要不良肢体事件(MALE),如截肢和急性肢体缺血。因此,保守治疗的目的是降低MACE和MALE的发生率。对于间歇性跛行患者,目标还包括延长步行距离。危险因素的管理包括戒烟、他汀类药物治疗、降低低密度脂蛋白胆固醇(目标值<55mg/dL且降至基线值的至少50%)、血糖正常化以及治疗动脉高血压(目标值<140/90mmHg)。此外,抗栓治疗应包括抗血小板治疗(阿司匹林100mg或氯吡格雷75mg)。对于血栓形成风险高且出血风险低的患者,建议联合使用100mg阿司匹林和2×2.5mg利伐沙班。对于间歇性跛行患者,强烈推荐运动疗法。尽管风险很高,但在临床实践中,尤其是PAD患者常常治疗不足。

相似文献

1
[Conservative treatment of peripheral arterial disease].外周动脉疾病的保守治疗
Inn Med (Heidelb). 2022 Jun;63(6):579-583. doi: 10.1007/s00108-022-01342-8. Epub 2022 May 9.
2
[Principles of angiology in lower extremity arterial disease (LEAD)].[下肢动脉疾病(LEAD)的血管病学原理]
Herz. 2020 Apr;45(2):201-208. doi: 10.1007/s00059-020-04896-1.
3
4
Do we have a unified consensus on antithrombotic management of PAD?我们是否对 PAD 的抗栓治疗有统一的共识?
Int Angiol. 2021 Jun;40(3):229-239. doi: 10.23736/S0392-9590.21.04597-1. Epub 2021 Mar 19.
5
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.利伐沙班联合或不联合阿司匹林治疗稳定的外周动脉或颈动脉疾病患者:一项国际、随机、双盲、安慰剂对照试验。
Lancet. 2018 Jan 20;391(10117):219-229. doi: 10.1016/S0140-6736(17)32409-1. Epub 2017 Nov 10.
6
Antiplatelet agents for intermittent claudication.用于间歇性跛行的抗血小板药物。
Cochrane Database Syst Rev. 2011 Nov 9(11):CD001272. doi: 10.1002/14651858.CD001272.pub2.
7
Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial.利伐沙班与阿司匹林用于有症状的下肢外周动脉疾病患者:COMPASS随机临床试验的亚组分析
JAMA Cardiol. 2021 Jan 1;6(1):21-29. doi: 10.1001/jamacardio.2020.4390.
8
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).依洛尤单抗降低低密度脂蛋白胆固醇水平及外周动脉疾病患者的结局:来自 FOURIER 试验(在高风险人群中用 PCSK9 抑制剂进行进一步心血管结局研究)的见解。
Circulation. 2018 Jan 23;137(4):338-350. doi: 10.1161/CIRCULATIONAHA.117.032235. Epub 2017 Nov 13.
9
Antithrombotic therapy in peripheral arterial disease.外周动脉疾病的抗栓治疗
Front Cardiovasc Med. 2022 Oct 13;9:927645. doi: 10.3389/fcvm.2022.927645. eCollection 2022.
10
Medical and lifestyle management of peripheral arterial disease.外周动脉疾病的医学与生活方式管理
J Vasc Surg. 2018 Nov;68(5):1595-1606. doi: 10.1016/j.jvs.2018.07.027.

本文引用的文献

1
Diabetes Mellitus and Its Impact on Patient-Profile and In-Hospital Outcomes in Peripheral Artery Disease.糖尿病及其对周围动脉疾病患者特征和住院结局的影响。
J Clin Med. 2021 Oct 28;10(21):5033. doi: 10.3390/jcm10215033.
2
The tobacco endgame-eradicating a worsening epidemic.烟草终局——消除日益严重的流行问题。
Eur Heart J. 2021 Aug 21;42(32):3044-3048. doi: 10.1093/eurheartj/ehab245.
3
The ESC Working Group on Aorta & Peripheral Vascular Diseases.欧洲心脏病学会主动脉与外周血管疾病工作组
Eur Heart J. 2020 Nov 21;41(44):4221-4223. doi: 10.1093/eurheartj/ehaa620.
4
Exercise-induced improvement of microvascular phenotype and reprogramming of p66Shc DNA methylation.运动诱导的微血管表型改善及p66Shc DNA甲基化重编程。
Eur Heart J. 2019 Dec 21;40(48):3948-3949. doi: 10.1093/eurheartj/ehz830.
5
The year in cardiology 2016: peripheral circulation.2016年心脏病学领域:外周循环
Eur Heart J. 2017 Apr 7;38(14):1028-1033. doi: 10.1093/eurheartj/ehw643.